Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 4Gynecologic 3Head & Neck 2Breast 2Myeloid 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Gemcitabine 2Azacitidine 2sargramostim 1pemigatinib 1pembrolizumab 1motexafin gadolinium 1incomplete Freund's adjuvant 1cc-486 1Trastuzumab 1Tinzaparin 1Quality of Life 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Panitumumab 1Molecular Diagnostic Techniques 1Injections 1Immunotherapy 1Immunoenzyme Techniques 1Imatinib Mesylate 1IFL protocol 1Flow Cytometry 1Epoetin Alfa 1Drug Therapy 1Doxorubicin 1Docetaxel 1Cisplatin 1Cetuximab 1Biological Therapy 1Antineoplastic Protocols 14-phenylbutyric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × IFL protocol × Myeloid × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡